Hence, inhibition through FcγRIIB is critical for balanced immunity, and a single-nucleotide polymorphism leading to I232T substitution within the transmembrane domain of FcγRIIB is associated with an increased risk of autoimmune diseases [41]. This evidence concerns the gene FCGR2B and autoimmune disease.